Methylene blue is used primarily in the treatment of patients with methemoglobinemia. Most recently, methylene blue has been used as a treatment for refractory distributive shock from a variety of causes such as sepsis and anaphylaxis. Many studies suggest that the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway plays a significant role in the pathophysiology of distributive shock. There are some experimental and clinical experiences with the use of methylene blue as a selective inhibitor of the NO-cGMP pathway. Methylene blue may play a role in the treatment of distributive shock when standard treatment fails. © 2013 American College of Medical Toxicology.
CITATION STYLE
Jang, D. H., Nelson, L. S., & Hoffman, R. S. (2013). Methylene Blue for Distributive Shock: A Potential New Use of an Old Antidote. Journal of Medical Toxicology, 9(3), 242–249. https://doi.org/10.1007/s13181-013-0298-7
Mendeley helps you to discover research relevant for your work.